ArticleCanadian journal of gastroenterology & hepatology2026
Beyond the INR: Thromboelastography Carries Prognostic Information in Critically Ill Patients With Cirrhosis.
Article in Canadian journal of gastroenterology & hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the INR: Thromboelastography Carries Prognostic Information in Critically Ill Patients With Cirrhosis.Canadian journal of gastroenterology & hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn patients with cirrhosis, prolonged international normalized ratio (INR) is primarily driven by liver synthetic dysfunction. Thromboelastography more accurately reflects coagulability and can also predict short-term mortality. Nevertheless, INR is used to define coagulation failure in the European Foundation for the Study of Chronic Liver Failure criteria for acute-on-chronic liver failure (ACLF).
aimTo evaluate the association between TEG parameters and mortality in critically ill patients with cirrhosis and to justify future investigation into TEG as a prognostic tool in ACLF.
methodsWe performed a retrospective study of 52 patients with cirrhosis admitted to the intensive care unit (ICU) who had TEG performed during their ICU admission prior to the administration of any blood products. We assessed the association between TEG parameters and 28-day mortality.
resultsPatients who did not survive beyond 28 days generally had more hypocoagulable TEG parameters (R time: 10.0 vs. 7.6, p = 0.03; K time: 3.4 vs. 2.2, p = 0.003; alpha angle: 53.1 vs. 63.5, p = 0.002; MA: 49.2 vs. 60.2, p = 0.001). Although global assessment of TEG demonstrated a state of rebalanced hemostasis among critically ill patients with cirrhosis, patients meeting diagnostic criteria for ACLF tended to have more hypocoagulable TEG parameters as compared to those who did not (coagulation index: 0.2 vs. 2.0, p = 0.004). As proof of concept, MA was incorporated into the definition of ACLF to replace INR as a marker of coagulation failure (TEG-ACLF). The area under the curve (AUC) for TEG-ACLF was 0.83 (0.72-0.95) compared to 0.8 (0.68-0.92) for the current ACLF-CLIF grading, with 9.6% (5/52) of patients being reclassified into a different ACLF grade.
conclusionHypocoagulable TEG parameters are associated with increased 28-day mortality in critically ill patients with cirrhosis, and incorporation of TEG parameters into a modified definition for ACLF may result in improved prediction of short-term mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.